Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 12;47(4):947–957. doi: 10.1007/s00259-019-04530-1

Table 2.

Hematotoxicity, hepatotoxicity and nephrotoxicity after PRRT according to CTCAE v.5.0.

Group Status WBC PLT Hb ALT AST ALP Cr
100mCiTATE Baseline 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0
Post-therapy 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0 5 CTC-0
30mCi EBTATE Baseline 7 CTC-0 7 CTC-0 7 CTC-0 7 CTC-0 7 CTC-0 7 CTC-0 7 CTC-0
Post-therapy 7 CTC-0 6 CTC-0
1 CTC-1
7 CTC-0 6 CTC-0
1 CTC-2
6 CTC-0
1 CTC-2
7 CTC-0 7 CTC-0
50mCi EBTATE Baseline 6 CTC-0 5 CTC-0
1 CTC-2
6 CTC-0 6 CTC-0 6 CTC-0 6 CTC-0 6 CTC-0
Post-therapy 6 CTC-0 5 CTC-0
1 CTC-2
6 CTC-0 6 CTC-0 6 CTC-0 6 CTC-0 6 CTC-0
100mCi EBTATE Baseline 14 CTC-0 14 CTC-0 13 CTC-0
1 CTC-3
14 CTC-0 14 CTC-0 14 CTC-0 14 CTC-0
Post-therapy 14 CTC-0 12 CTC-0
2 CTC-3
12 CTC-0
1 CTC-1
1 CTC-3
13 CTC-0
1 CTC-2
13 CTC-0
1 CTC-2
13 CTC-0
1 CTC-1
14 CTC-0